Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
The surgical management of cervical cancer is highly tailored to the stage of the disease and the patient’s desire for future fertility. For micro-invasive cancer (Stage IA1), a Cone Biopsy (Conization) or Loop Electrosurgical Excision Procedure (LEEP) may be sufficient. These procedures remove the central portion of the cervix containing the tumor. If the margins are clear of cancer, no further treatment may be needed, preserving the uterus.
For visible early-stage tumors (Stage IB1, IIA1), the standard of care is a Radical Hysterectomy. Unlike a simple hysterectomy, which removes just the uterus and cervix, a radical hysterectomy involves removing the uterus, the cervix, the upper part of the vagina (vaginal cuff), and the parametrium (the supporting connective tissue). This wider resection is necessary because cervical cancer spreads laterally through the parametrial lymphatics.
This surgery can be performed via open laparotomy (large incision), laparoscopy, or robotic-assisted surgery. However, recent high-level evidence (the LACC trial) has suggested that open surgery may offer better survival rates for cervical cancer compared to minimally invasive approaches, leading to a resurgence of the traditional open technique for radical cases. During the surgery, a Pelvic Lymphadenectomy is performed, removing the lymph nodes in the pelvis to check for microscopic spread.
For young women diagnosed with early-stage cervical cancer who wish to preserve the ability to carry a pregnancy, a Radical Trachelectomy is a revolutionary option. This complex procedure involves removing the cervix, the upper vagina, and the parametrium (just like a radical hysterectomy), but surgically detaching the uterine body and preserving it. The remaining uterus is then reconnected to the vagina, and a permanent suture (cerclage) is placed at the bottom of the uterus to act as an artificial cervix during future pregnancies.
Candidates for this surgery must be carefully selected: the tumor must be small (usually <2cm), there must be no spread to lymph nodes, and the upper cervical canal must be free of cancer. This procedure allows for natural conception or assisted reproduction. Pregnancies following trachelectomy are considered high-risk due to the potential for preterm birth, necessitating delivery via Cesarean section, but the procedure has allowed thousands of women to become mothers after a cancer diagnosis.
For tumors that are larger (Stage IB3) or have spread beyond the cervix (Stage IIB and above), surgery is not the primary treatment. Instead, the global standard is Concurrent Chemoradiation (CCRT). This approach combines External Beam Radiation Therapy (EBRT) with weekly doses of chemotherapy, typically Cisplatin.
In this context, chemotherapy acts as a “radiosensitizer.” It weakens the cancer cells’ ability to repair DNA damage, making the radiation more effective. The external radiation is delivered daily over 5 to 6 weeks, targeting the cervix, the uterus, the parametrium, and the pelvic lymph nodes. By treating the entire pelvic basin, chemoradiation addresses both the primary tumor and potential microscopic spread in the nodes without the morbidity of a massive surgery that would likely fail to clear the parametrial disease.
This non-surgical approach is highly effective and curative for a significant proportion of women with locally advanced disease. The integration of intensity-modulated radiation therapy (IMRT) allows for precise shaping of the radiation beams, minimizing the dose to the bladder and bowel and reducing long-term side effects.
An essential component of the curative radiation protocol is Brachytherapy. After the external beam radiation has shrunk the tumor, brachytherapy delivers a very high dose of radiation directly to the residual tumor from the inside. This is known as an “internal boost.”
During this procedure, performed under anesthesia, hollow applicators (tandem and ovoids, or ring) are inserted through the vagina and into the uterine cavity. A radioactive source (usually Iridium-192) travels through these tubes, dwelling at specific points to deliver radiation. Because the source is inside the tumor, the radiation dose drops off extremely rapidly—following the inverse-square law. This allows the cancer to receive a tumoricidal dose that is significantly higher than what could be safely delivered from the outside, while sparing the nearby bladder and rectum.
Image-Guided Brachytherapy (IGBT), using MRI or CT to plan the dose, represents the state of the art. It ensures the high-dose zone conforms perfectly to the remaining tumor shape. Omitting brachytherapy in favor of more external radiation results in significantly lower survival rates; it is a non-negotiable part of curative treatment for locally advanced cervical cancer.
For patients with distant metastasis (Stage IVB) or recurrent disease that cannot be treated with local surgery or radiation, systemic therapy is the mainstay. The backbone of treatment has traditionally been platinum-based chemotherapy (Cisplatin or Carboplatin) combined with Paclitaxel.
A significant advancement was the addition of Bevacizumab, a targeted therapy that inhibits VEGF (Vascular Endothelial Growth Factor). Cervical cancers are heavily dependent on angiogenesis (new blood vessel formation). Bevacizumab blocks this process, starving the tumor. Adding this drug to chemotherapy has been shown to extend overall survival.
Most recently, Immunotherapy has entered the arena. The checkpoint inhibitor Pembrolizumab is approved for patients whose tumors express PD-L1. By blocking the PD-1/PD-L1 pathway, this drug removes the “brakes” on the immune system, allowing T cells to attack the cancer. For patients with persistent, recurrent, or metastatic cervical cancer, the combination of chemotherapy, bevacizumab, and immunotherapy is becoming the new standard, offering hope for long-term control even in advanced scenarios.
Send us all your questions or requests, and our expert team will assist you.
Once the cancer spreads sideways into the parametrium (Stage IIB), it becomes technically impossible to surgically cut around the tumor with a “clear margin” without cutting vital nerves and blood vessels. Attempting surgery often leaves cancer behind. Radiation, however, can penetrate these tissues and effectively treat the spread, offering a better chance of cure than incomplete surgery.
Side effects are generally localized. Patients may experience vaginal irritation, discharge, or spotting. Temporary urinary frequency or burning can occur. Long-term, there is a risk of vaginal stenosis (narrowing and shortening of the vagina), which is why vaginal dilator therapy is recommended after treatment to maintain elasticity.
If you are receiving the standard weekly Cisplatin with radiation, significant hair loss (alopecia) is rare. This regimen usually causes thinning rather than total loss. However, if you are treated for metastatic disease with higher doses of chemotherapy involving Paclitaxel, total hair loss is expected, though it is temporary.
A regular (simple) hysterectomy removes just the uterus and cervix. A radical hysterectomy is a cancer operation; it removes the uterus, cervix, the upper 2cm of the vagina, and the tissues surrounding the cervix (parametrium). It also involves removing lymph nodes. It is a more extensive surgery with a longer recovery time.
Not yet. Immunotherapy (like Pembrolizumab) is currently approved for patients with recurrent or metastatic cervical cancer, usually combined with chemotherapy. Its use depends on whether your tumor tests positive for PD-L1. Testing your tumor biopsy helps your doctor decide if this treatment will work for you.
Your Comparison List (you must select at least 2 packages)
